<DOC>
	<DOCNO>NCT00130715</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Seprafilm reduce incidence bowel obstruction evaluate incidence serious adverse event ( SAEs ) associate use Seprafilm occur within 30 day postoperatively , incidence abdominopelvic abscess within 6 month postoperatively .</brief_summary>
	<brief_title>Seprafilm Reduction Incidence Bowel Obstruction General Surgery</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Obstruction</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Patients undergo colon and/or rectal resection and/or adhesiolysis treatment bowel obstruction Patients medical condition disease 5year survival expect Patients undergo laparoscopy Patients undergo surgery treatment acute abdominal trauma Patients abscess ( abdominal pelvic ) present initial surgery Patients history pulmonary embolus deep vein thrombosis ( DVT ) within 1 year surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Patients undergoing variety abdominal surgical procedure</keyword>
</DOC>